Shield Therapeutics plc
Save
–
Market cap
–
Current P/E
53.76x
Forward P/E
About
Health care
Sector
Drug Manufacturers - Specialty & Generic
Industry
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease.
Similar securities
Based on sector and market capitalization
Report issue